Regulatory compliance – Page 56

Team unprepared for interviews during FDA/EMA inspection – inspection playbook and preparation strategy

Preparing Your Team for Successful Interviews During FDA and EMA Inspections In the highly regulated pharmaceutical industry, regulatory inspections are critical checkpoints to ensure compliance with Good Manufacturing Practices (GMP).…

GDP errors in batch records during audit trail review – ALCOA+ gap analysis

Addressing GDP Errors in Batch Records During Audit Trail Reviews Using ALCOA+ Gap Analysis GDP errors in batch records during audit trail review pose significant risks to pharmaceutical manufacturing’s integrity…

CAPA follow-up weak before regulatory inspection – CAPA closure verification

Addressing Deficiencies in CAPA Follow-Up Prior to Regulatory Inspections In pharmaceutical manufacturing, efficient Corrective and Preventive Actions (CAPA) are crucial for maintaining compliance with Good Manufacturing Practices (GMP) and preparing…

Data attribution unclear during routine operations – evidence pack inspectors expect

Navigating Data Attribution Issues during Routine Operations in Pharmaceutical Manufacturing In the complex landscape of pharmaceutical manufacturing, ensuring data attribution clarity is critical. Without it, organizations expose themselves to significant…

Inspection readiness untested during FDA/EMA inspection – inspection playbook and preparation strategy

Practical Guide to Enhancing Inspection Readiness for FDA and EMA Audits The pharmaceutical industry faces constant scrutiny from regulatory bodies such as the FDA and EMA, and inspection readiness is…

Inspection readiness untested during FDA/EMA inspection – inspection playbook and preparation strategy

Preparing for FDA/EMA Inspections: A Comprehensive Playbook for Inspection Readiness Pharmaceutical manufacturers are regularly subject to inspections by regulatory bodies such as the FDA, EMA, and MHRA. Many times, the…

Illegible entries in controlled records during deviation investigation – ALCOA+ gap analysis

Managing Illegible Entries in Controlled Records During Deviation Investigations Illegible entries in controlled records can significantly impact the integrity of data during deviation investigations in pharmaceutical manufacturing. These inconsistencies can…

Mock audit findings ignored during FDA/EMA inspection – evidence pack inspectors expect

How to Address Mock Audit Findings Before FDA/EMA Inspections During pharmaceutical manufacturing, the gap between passing a mock audit and facing an actual FDA or EMA inspection can often reveal…

Data attribution unclear during deviation investigation – inspection citation risk and mitigation

Mitigating Risks of Unclear Data Attribution During Deviation Investigations In pharmaceutical manufacturing, data reliability is paramount. The implications of unclear data attribution during a deviation investigation can lead to serious…

CAPA follow-up weak during remediation tracking – evidence pack inspectors expect

Strengthening CAPA Follow-Up During Remediation Tracking for Inspection Readiness In pharmaceutical manufacturing, a strong Corrective and Preventive Action (CAPA) process is crucial for maintaining compliance with Good Manufacturing Practice (GMP)…

Illegible entries in controlled records during record archival – inspection citation risk and mitigation

Mitigating Risks of Illegible Entries in Controlled Records During Record Archival In pharmaceutical manufacturing, maintaining the integrity of documentation is paramount. One of the critical risks that can jeopardize regulatory…

Mock audit findings ignored during FDA/EMA inspection – preventing escalation to warning letter

How to Address Mock Audit Findings Before FDA/EMA Inspections to Prevent Warning Letters In the pharmaceutical industry, the stakes are high when regulatory inspections occur. This article focuses on a…